Rovin Capital UT ADV lessened its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 28.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 6,951 shares of the biopharmaceutical company's stock after selling 2,708 shares during the quarter. Rovin Capital UT ADV's holdings in Gilead Sciences were worth $642,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors also recently modified their holdings of the company. Bellevue Group AG boosted its stake in Gilead Sciences by 18.2% in the 3rd quarter. Bellevue Group AG now owns 46,027 shares of the biopharmaceutical company's stock valued at $3,859,000 after buying an additional 7,093 shares in the last quarter. Quantinno Capital Management LP boosted its stake in Gilead Sciences by 149.5% in the 3rd quarter. Quantinno Capital Management LP now owns 81,620 shares of the biopharmaceutical company's stock valued at $6,843,000 after buying an additional 48,910 shares in the last quarter. Legal & General Group Plc boosted its stake in Gilead Sciences by 0.8% in the 2nd quarter. Legal & General Group Plc now owns 12,414,268 shares of the biopharmaceutical company's stock valued at $851,743,000 after buying an additional 93,068 shares in the last quarter. IRON Financial LLC acquired a new stake in Gilead Sciences in the 3rd quarter valued at $830,000. Finally, Wealth Enhancement Advisory Services LLC boosted its stake in Gilead Sciences by 12.9% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 323,011 shares of the biopharmaceutical company's stock valued at $27,081,000 after buying an additional 36,895 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company's stock.
Gilead Sciences Trading Down 0.8 %
NASDAQ:GILD traded down $0.73 on Thursday, reaching $91.65. The company's stock had a trading volume of 8,948,278 shares, compared to its average volume of 6,722,391. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26. The firm has a market cap of $114.22 billion, a PE ratio of 1,018.33, a PEG ratio of 1.27 and a beta of 0.18. The business's 50-day moving average price is $91.97 and its two-hundred day moving average price is $83.76. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $98.90.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping the consensus estimate of $1.58 by $0.44. The company had revenue of $7.55 billion during the quarter, compared to analysts' expectations of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. Gilead Sciences's revenue for the quarter was up 7.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.29 earnings per share. Equities research analysts anticipate that Gilead Sciences, Inc. will post 4.36 earnings per share for the current fiscal year.
Gilead Sciences Announces Dividend
The company also recently disclosed a quarterly dividend, which was paid on Monday, December 30th. Stockholders of record on Friday, December 13th were given a dividend of $0.77 per share. The ex-dividend date of this dividend was Friday, December 13th. This represents a $3.08 annualized dividend and a dividend yield of 3.36%. Gilead Sciences's dividend payout ratio is currently 3,422.22%.
Analyst Ratings Changes
GILD has been the topic of a number of recent analyst reports. Sanford C. Bernstein initiated coverage on Gilead Sciences in a research note on Thursday, October 17th. They issued an "outperform" rating and a $105.00 price objective on the stock. Piper Sandler boosted their price objective on Gilead Sciences from $95.00 to $105.00 and gave the stock an "overweight" rating in a research note on Thursday, November 7th. The Goldman Sachs Group boosted their price objective on Gilead Sciences from $74.00 to $84.00 and gave the stock a "neutral" rating in a research note on Thursday, November 7th. Maxim Group lowered Gilead Sciences from a "buy" rating to a "hold" rating in a research note on Friday, November 8th. Finally, Bank of America reissued a "buy" rating and issued a $109.00 price objective on shares of Gilead Sciences in a research note on Tuesday, December 10th. Eleven equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have assigned a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $97.96.
Get Our Latest Report on Gilead Sciences
Insider Activity at Gilead Sciences
In related news, insider Merdad Parsey sold 25,590 shares of the stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the completion of the transaction, the insider now directly owns 99,599 shares of the company's stock, valued at approximately $9,113,308.50. This represents a 20.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total value of $228,375.00. Following the transaction, the chief financial officer now directly owns 129,873 shares of the company's stock, valued at $11,863,898.55. This trade represents a 1.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 456,234 shares of company stock valued at $42,130,461. Insiders own 0.29% of the company's stock.
Gilead Sciences Profile
(
Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Featured Articles
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
